Cognition Therapeutics Appoints Anthony O. Caggiano M.D., Ph.D. to the Position of Chief Medical Officer
Press Release
, June 5th, 2019
Cognition Therapeutics Expands Clinical Expertise on Medical Advisory Board with Addition of Drs. Mary Sano and Philip Scheltens
Press Release
, April 5th, 2019
Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors
Press Release
, March 26th, 2019
Cognition Therapeutics Receives European Patent Covering its Alzheimer’s Disease Candidate, Elayta™
Press Release
, February 21st, 2019
Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™
Press Release
, February 19th, 2019
Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease
Press Release
, November 27th, 2018
Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease
Press Release
, November 8th, 2018
Cognition Therapeutics to Sponsor Third International Symposium on Sigma-2 Receptors: Role in Health and Disease during the Society for Neuroscience Annual Meeting
Press Release
, October 24th, 2018
Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant for Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease
Intrado
, October 2nd, 2018